Cornerstone Therapeutics has signed an agreement to acquire exclusive US marketing rights to Pertzye (pancrelipase) from Digestive Care (DCI). Pertzye, the pancreatic enzyme product, is indicated for the treatment of exocrine pancreatic ...
Tags: Cornerstone, Digestive Care
Digestive Care (DCI) has gained FDA approval for its new drug application (NDA) for Pertzye, a pancreatic enzyme product containing bicarbonate-buffered enteric-coated microspheres. Pertzye is indicated for the treatment of Exocrine ...